• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Pheton Holdings Ltd

    9/2/25 4:20:16 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $PTHL alert in real time by email
    6-K 1 ea0255630-6k_pheton.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of September 2025

     

    Commission File Number: 001-42263

     

    Pheton Holdings Ltd

     

    Room 306, NET Building,

    Hong Jun Ying South Road, Chaoyang District,

    Beijing, China

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒          Form 40-F ☐

     

     

     

     

     

    Information Contained in this Form 6-K Report

     

    Entry into an Advisory Services Agreement.

     

    On August 28, 2025, Pheton Holdings Ltd (the “Company”) entered into an Advisory Services Agreement (the “Agreement”) with Comane International Group Ltd, a company organized under the laws of the British Virgin Islands (“Consultant”) and controlled by a third-party. Pursuant to the Agreement, the Company engaged Consultant to provide advisory services to the Company with respect to mergers and acquisitions strategies and general corporate development matters, including but not limited to conducting market research, evaluating and implementing capital restructuring plans, advising on transaction structuring, valuation analysis and due diligence support, facilitating communications with relevant government agencies to obtain necessary approvals, and coordinating with other professional parties.

     

    The term of the Agreement is five (5) years. As consideration for such services, the Company agreed to issue to Consultant warrants (the “Warrants”) to purchase up to 4,000,000 Class A ordinary shares of the Company, with an exercise price of US$0.80 per share and an expiration date of five (5) years from the date of issuance. The Warrants are not exercisable until six (6) months after the date of the Agreement and may only be exercised upon the written consent of the Company’s Chief Executive Officer, who will determine in good faith, after consultation with the Board of Directors if deemed necessary, whether the Consultant has satisfactorily performed its advisory services under the Agreement.

     

    Either party may terminate the Agreement upon not less than thirty (30) days’ prior written notice. In the event of termination, any Warrants that remain unexercised shall be returned to the Company and cancelled. If any unearned portion of the Warrants (calculated on a straight-line, monthly pro rata basis over the original five-year term) has already been exercised, the treatment of such exercised Warrants, including any clawback or repayment obligations, will be governed by the provisions set forth in the Agreement.

     

    Forward Looking Statements

     

    Certain statements in this Report are not historical facts, including, without limitation, statements relating to the Agreement between the Company and Consultant, including the ability to carry out, and the timing and effectiveness of, the services contemplated by the Agreement, the issuance, exercisability and treatment of the Warrants, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” “continues,” or similar expressions. Such statements are based upon the current beliefs and expectations of management of the Company. These statements are subject to risks, uncertainties, changes in circumstances, assumptions and other important factors, many of which are outside management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Actual results may differ materially from current expectations because of numerous risks and uncertainties, including, among others: (1) the risk that the anticipated benefits of the Agreement may not be realized in a timely manner or at all; (2) the risk that the Consultant may not satisfactorily perform its obligations under the Agreement, resulting in the Warrants not becoming exercisable; (3) the risk of disputes or legal proceedings relating to the Agreement, which may result in significant costs of defense, indemnification, or liability; (4) the risk that the issuance of the Warrants or any related transactions may be delayed, prohibited, or require approvals that are not obtained; and (5) conditions beyond the Company’s control, including macroeconomic conditions, market volatility, or geopolitical events, that could affect the Company’s ability to implement its business strategies or realize the intended benefits of the Agreement. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in Company’s public filings with the U.S. Securities and Exchange Commission from time to time, including the Company’s most recent Annual Report on Form 20-F for the year ended December 31, 2024. The Company’s shareholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Pheton Holdings Ltd
         
    Date: September 2, 2025 By: /s/ Jianfei Zhang
      Name:  Jianfei Zhang
      Title:

    Chief Executive Officer and

    Chairman of the Board of Directors

     

     

    2

     

    Get the next $PTHL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTHL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTHL
    SEC Filings

    View All

    SEC Form 6-K filed by Pheton Holdings Ltd

    6-K - Pheton Holdings Ltd (0001970544) (Filer)

    1/13/26 4:00:30 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by Pheton Holdings Ltd

    6-K - Pheton Holdings Ltd (0001970544) (Filer)

    12/22/25 7:43:23 AM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by Pheton Holdings Ltd

    6-K - Pheton Holdings Ltd (0001970544) (Filer)

    12/16/25 12:58:56 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $PTHL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pheton Holdings Ltd Announces Corporate Name Change and Stock Ticker Symbol Change

    BEIJING, China, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the "Company" or "Pheton"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, announced today that it will change its corporate name to iTonic Holdings Ltd, and change its stock ticker symbol to "ITOC" (collectively, the "Corporate Events"). The Company anticipates that the Corporate Events will be effective upon the commencement of trading on the Nasdaq Capital Market on January 16, 2026 (U.S. Eastern Time), at which time the Company's Class A ordinary shares will cease trading under the current ticker symbol "PTHL" and will begin tradi

    1/13/26 8:30:00 AM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Pheton Holdings Ltd Announces Closing of Share Acquisition with iTonic Corporation

    Beijing, China, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ:PTHL) ("Pheton" or the "Company"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced the successful completion of its acquisition of 51% of the total outstanding shares of iTonic Corporation (the "Target"), a U.S.-based integrated home health AI company that combines AI, medical device automation, and easier access to clinical expertise to support continuity of care in the home (the "Share Acquisition"). This strategic acquisition aligns with the Company's commitment to enhancing its portfolio in the healthcare tech

    12/5/25 4:05:00 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Pheton Holdings Ltd Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

    Beijing, China, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ:PTHL) (the "Company"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced, on October 20, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that based on the closing bid price of the Class A ordinary shares of the Company for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. Th

    10/23/25 4:15:00 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care